GHSI - Guardion Health Sciences Inc Stock Price, Fair Value and News

8.51USD-0.11 (-1.28%)Delayed

Market Summary

USD8.51-0.11

Delayed

-1.28%

GHSI Stock Price

View Fullscreen

GHSI RSI Chart

GHSI Valuation

Market Cap

10.9M

Price/Earnings (Trailing)

-2.13

Price/Sales (Trailing)

0.91

Price/Free Cashflow

-3.37

GHSI Price/Sales (Trailing)

GHSI Profitability

Return on Equity

-150.02%

Return on Assets

-49.22%

Free Cashflow Yield

-29.72%

GHSI Fundamentals

GHSI Revenue

Revenue (TTM)

12.1M

Rev. Growth (Yr)

-5.84%

Rev. Growth (Qtr)

2.17%

GHSI Earnings

Earnings (TTM)

-5.1M

Earnings Growth (Yr)

-990.42%

Earnings Growth (Qtr)

-1.2K%

Breaking Down GHSI Revenue

Last 7 days

3.4%

Last 30 days

5.5%

Last 90 days

1.2%

Trailing 12 Months

35.3%

How does GHSI drawdown profile look like?

GHSI Financial Health

Current Ratio

8.17

GHSI Investor Care

Shares Dilution (1Y)

1.33%

Diluted EPS (TTM)

-4.01

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	12.1M	0	0	0
2023	11.9M	11.4M	12.0M	12.2M
2022	9.4M	11.4M	11.0M	11.0M
2021	1.9M	1.9M	4.8M	7.2M
2020	906.1K	1.8M	1.9M	1.9M
2019	991.7K	1.0M	898.8K	902.9K
2018	574.5K	735.3K	966.8K	942.2K
2017	167.8K	198.4K	227.4K	437.4K
2016	119.9K	126.9K	134.0K	141.0K
2015	0	0	0	112.8K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Guardion Health Sciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 10, 2023	radoff bradley louis	bought	242,353	7.59727	31,900	-
Jan 09, 2023	radoff bradley louis	bought	583,487	6.87904	84,821	-
Jan 06, 2022	scholtes bret	sold (taxes)	-24,163	0.65	-37,175	ceo and president
Aug 31, 2021	scholtes bret	bought	6,760	1.2291	5,500	ceo and president
Aug 30, 2021	gagliano donald a	bought	6,250	1.25	5,000	-
Aug 30, 2021	scholtes bret	bought	5,655	1.2568	4,500	ceo and president
Aug 20, 2021	weingarten robert n	acquired	11,400	1.14	10,000	-
Jan 06, 2021	scholtes bret	acquired	-	-	916,023	chief executive officer
Jan 06, 2021	scholtes bret	acquired	-	-	152,671	ceo and president
Oct 30, 2019	evans david w	acquired	664	0.332	2,000	chief science officer

Which funds bought or sold GHSI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-12.3	2,930	9,007	-%
May 15, 2024	Federation des caisses Desjardins du Quebec	new	-	306	306	-%
May 15, 2024	MORGAN STANLEY	unchanged	-	2,428	5,947	-%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	reduced	-0.53	138,000	341,000	-%
May 13, 2024	UBS Group AG	new	-	10,577	10,577	-%
May 13, 2024	FMR LLC	new	-	9.00	9.00	-%
May 10, 2024	VANGUARD GROUP INC	unchanged	-	54,729	134,039	-%
May 10, 2024	BlackRock Inc.	unchanged	-	36,961	90,521	-%
May 10, 2024	OSAIC HOLDINGS, INC.	unchanged	-	22.00	54.00	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	unchanged	-	33.00	81.00	-%

Are Funds Buying or Selling GHSI?

Are funds buying GHSI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GHSI

No. of Funds

Unveiling Guardion Health Sciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 06, 2024	intracoastal capital, llc	3.8%	50,000	SC 13G/A
Feb 05, 2024	hudson bay capital management lp	9.99%	141,535	SC 13G/A
Feb 08, 2023	hudson bay capital management lp	9.74%	6,651,000	SC 13G
Feb 08, 2023	intracoastal capital, llc	7.5%	5e+06	SC 13G/A
Jan 10, 2023	radoff bradley louis	2.0%	25,100	SC 13G/A
Nov 30, 2022	radoff bradley louis	1.0%	620,000	SC 13G
Feb 28, 2022	intracoastal capital, llc	8.1%	5e+06	SC 13G
Feb 12, 2021	grier edward b. iii	1.22%	1,079,089	SC 13G/A
Jan 27, 2020	empery asset management, lp	4.99%	5,848,612	SC 13G/A
Jan 13, 2020	sabby management, llc	4.99%	3,741,630	SC 13G/A

Recent SEC filings of Guardion Health Sciences Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	DEFA14A	DEFA14A
May 15, 2024	8-K	Current Report
May 13, 2024	10-Q	Quarterly Report
May 06, 2024	424B5	Prospectus Filed
May 03, 2024	EFFECT	EFFECT
May 02, 2024	8-K	Current Report
Apr 29, 2024	10-K/A	Annual Report
Apr 09, 2024	8-K	Current Report
Apr 08, 2024	DEFM14A	DEFM14A
Apr 03, 2024	3	Insider Trading

Peers (Alternatives to Guardion Health Sciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	372.2B	85.6B	6.82%	-1.69%	9.67	4.35	5.68%	202.39%
MRK	332.3B	61.4B	4.65%	15.09%	144.1	5.41	6.11%	-82.30%
AMGN	167.7B	29.5B	18.35%	39.38%	44.55	5.68	12.76%	-52.47%
PFE	162.3B	57.8B	12.71%	-21.46%	129.52	2.81	76.51%	-86.81%
GILD	84.4B	27.4B	1.23%	-13.37%	174.21	3.07	1.51%	-91.32%
TEVA	18.4B	16.0B	23.52%	97.09%	-37.29	1.15	7.23%	71.10%
MID-CAP
ALKS	4.1B	1.7B	0.67%	-19.91%	9.41	2.37	54.01%	364.56%
PRGO	4.1B	4.6B	-0.70%	-10.77%	-528.11	0.89	-0.06%	94.55%
BHC	2.5B	9.0B	-21.94%	-21.03%	-5.45	0.28	10.01%	-27.45%
AMPH	2.1B	676.2M	8.56%	-0.82%	13.75	3.14	30.38%	66.04%
SMALL-CAP
TLRY	1.5B	743.2M	15.12%	-18.85%	-4.35	2.06	24.65%	80.36%
TXMD	25.8M	1.3M	18.52%	-47.17%	-3.49	19.84	-98.14%	-104.71%
ACRX	18.4M	89.6M	6.93%	25.60%	-1.29	0.19	287.27%	-129.41%
AGRX	2.5M	21.5M	2.70%	-90.89%	-0.32	0.12	66.16%	61.83%
ACOR	633.5K	115.7M	-50.00%	-97.38%	0	0.01	-2.22%	-352.48%

Guardion Health Sciences Inc News

Latest updates

Guardion Health Sciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	2.2%	3,000	2,936	3,337	2,790	3,186	2,726	2,664	3,275	2,385	2,627	3,149	1,224	233	200	253	1,191	246	238	161	261	243
Gross Profit	-12.6%	1,179	1,350	1,460	1,249	1,335	936	1,088	1,400	1,096	1,064	1,388	559	100	-878	139	546	137	158	90.00	164	149
Operating Expenses	12.2%	2,733	2,436	2,233	2,262	2,799	12,286	2,828	3,111	3,717	15,585	4,404	5,099	2,770	2,477	2,291	1,255	2,473	4,247	2,503	2,976	1,331
S&GA Expenses	-2.8%	362	372	319	415	599	486	526	389	669	609	778	441	458	275	167	519	489	646	448	409	354
R&D Expenses	3884.9%	3.00	79.50*	11.00	77.00	63.00	31.00	60.00	96.00	7.00	11.00	16.00	17.00	21.00	51.00	34.00	45.00	31.00	56.00	32.00	78.00	29.00
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17.50*	4.00	2.00	2.00	3.00	4.00	234	18.00
Income Taxes	-	-	-	-	-	-	-20.84	-	-	-	-	-	11.00	9.00	-	-	-	-	-	-	-	-
Net Income	-1217.6%	-4,746	425	373	-1,172	533	-12,453	-822	3,656	-5,300	-14,520	-3,014	-4,540	-2,669	-3,374	-2,143	-707	-2,346	-4,055	-2,385	-3,052	-1,385
Net Income Margin	-3391.0%	-0.42*	0.01*	-1.06*	-1.22*	-0.77*	-1.35*	-1.55*	-1.68*	-2.92*	-3.42*	-2.83*	-6.66*	-4.74*	-	-	-	-	-	-	-	-
Free Cashflow	42.7%	-754	-1,317	-766	-408	-1,880	-1,363	-1,285	-2,574	-2,228	-1,564	-1,868	-4,865	-2,420	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-12.7%	10,407	11,918	12,878	13,474	14,419	21,686	28,228	29,835	31,621	23,461	38,613	41,285	44,702	9,861	12,159	14,034	15,283	12,877	8,955	5,698	3,971
Current Assets	-12.6%	10,382	11,885	12,840	13,431	14,373	21,637	17,811	19,099	20,568	12,069	14,867	16,547	43,996	9,095	11,334	13,171	14,303	11,868	6,132	2,856	544
Cash Equivalents	-11.9%	5,605	6,360	7,657	8,366	8,775	10,655	12,946	4,225	4,832	4,094	3,564	5,502	43,330	8,519	9,795	11,603	12,890	11,116	5,555	2,369	174
Inventory	-20.3%	2,134	2,677	2,451	2,513	3,061	3,119	1,953	1,710	822	368	793	956	289	385	1,284	1,235	759	311	320	319	304
Net PPE	-24.5%	25.00	33.00	38.00	43.00	46.00	49.00	54.00	75.00	94.00	111	269	246	266	286	306	305	383	375	389	304	265
Goodwill	-	-	-	-	-	-	-	-	-	-	-	11,893	11,988	-	-	-	-	-	-	1,564	1,564	1,564
Liabilities	85.4%	6,993	3,772	5,176	6,233	5,937	8,518	6,969	7,802	13,293	1,163	1,970	1,991	1,212	1,346	1,471	1,338	1,544	845	906	1,010	2,083
Current Liabilities	-3.6%	1,271	1,319	1,432	1,997	2,178	4,012	1,733	1,693	1,826	1,159	1,970	1,805	983	1,074	1,157	983	1,148	410	459	529	1,569
Shareholder's Equity	-58.1%	3,414	8,146	7,702	7,241	8,482	7,918	21,259	22,033	18,328	22,298	36,643	39,293	43,491	8,515	10,688	12,696	13,740	12,032	8,049	4,688	1,888
Retained Earnings	-5.1%	-98,313	-93,566	-93,990	-94,363	-93,191	-93,724	-81,270	-80,447	-84,103	-78,802	-64,281	-61,266	-56,726	-54,083	-50,709	-48,565	-47,858	-45,511	-41,455	-39,070	-36,018
Additional Paid-In Capital	0.0%	101,726	101,711	101,691	101,603	101,671	101,641	102,468	102,419	102,369	101,099	100,900	100,536	100,193	62,583	61,309	61,173	61,513	57,531	49,454	43,736	37,886
Shares Outstanding	0.7%	1,284	1,275	1,275	1,267	1,267	1,267	1,084	1,009	783	489	489	489	427	-	-	-	-	-	-	-	-
Float	-	-	-	-	9,900	-	-	-	9,200	-	-	-	41,800	-	-	-	37,500	-	-	-	20,800	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	42.7%	-754	-1,317	-766	-406	-1,879	-1,363	-1,282	-2,574	-2,226	-1,566	-1,792	-4,865	-2,420	-2,173	-1,819	-2,285	-1,735	-1,840	-1,695	-1,907	-586
Share Based Compensation	-	13.00	-	-	-	25.00	-	-	-	-	-	-	-	-	-	-251	1,402	68.00	78.00	57.00	187	56.00
Cashflow From Investing	-100.0%	-	20.00	-	-2.14	-1.65	-	10,004	1,990	-7,003	2,096	-145	-	-	-	6.00	-	-40.73	-7.97	-104	-54.12	-4.82
Cashflow From Financing	-	-	-	58.00	-	-5,250	4,323	-	-24.01	9,969	-1*	-	1*	37,231	897	6.00	999	3,551	7,409	4,986	4,156	94.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

GHSI Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue
Total revenue	$ 2,999,645	$ 3,185,689
Cost of goods sold
Total cost of goods sold	1,820,645	1,850,387
Gross Profit	1,179,000	1,335,302
Operating expenses
Research and development	3,168	62,734
Sales and marketing	361,908	598,655
General and administrative	1,834,669	2,050,252
Transaction costs related to pending disposition of business	529,690	87,668
Loss on disposal of fixed assets	3,366
Total operating expenses	2,732,801	2,799,309
Loss from operations	(1,553,801)	(1,464,007)
Other income (expense):
Change in fair value of warrant derivative liability	(3,268,588)	1,898,100
Interest income, net	75,645	98,998
Total other income (expense)	(3,192,943)	1,997,098
Net income (loss)	$ (4,746,744)	$ 533,091
Net income (loss) per common share - basic	$ (3.71)	$ 0.42
Net income (loss) per common share - diluted	$ (3.71)	$ 0.42
Weighted average common shares outstanding - basic	1,280,306	1,267,340
Weighted average common shares outstanding - diluted	1,280,306	1,267,340
Nutritional Supplements [Member]
Revenue
Total revenue	$ 2,918,526	$ 3,091,447
Cost of goods sold
Total cost of goods sold	1,776,479	1,781,827
Ocular Products [Member]
Revenue
Total revenue	81,119	94,242
Cost of goods sold
Total cost of goods sold	$ 44,167	$ 68,560

GHSI Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 5,605,035	$ 6,359,646
Accounts receivable, net	2,103,325	2,274,394
Inventories, net	2,134,213	2,677,112
Prepaid expenses and other current assets	539,209	573,780
Total current assets	10,381,782	11,884,932
Property and equipment, net	25,089	33,245
Total assets	10,406,871	11,918,177
Current liabilities
Accounts payable	413,294	614,122
Accrued expenses	857,805	704,912
Total current liabilities	1,271,099	1,319,034
Warrant derivative liability – long-term	5,721,688	2,453,100
Total liabilities	6,992,787	3,772,134
Commitments and contingencies
Stockholders’ equity
Preferred stock, $0.001 par value; 10,000,000 shares authorized
Common stock, $0.001 par value; 250,000,000 shares authorized; 1,284,156 shares and 1,275,238 issued and outstanding at March 31, 2024 and December 31, 2023, respectively	1,284	1,275
Additional paid-in capital	101,725,811	101,711,035
Accumulated deficit	(98,313,011)	(93,566,267)
Total stockholders’ equity	3,414,084	8,146,043
Total liabilities, preferred stock and stockholders’ equity	$ 10,406,871	$ 11,918,177

About Guardion Health Sciences Inc

Guardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported nutrition, medical foods, and dietary supplements in North America and Europe, and Internationally. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. It develops ImmuneSF, a nutraceutical formulation, as well as a portfolio of nutraceutical products under the NutriGuard brand. Further, it distributes medical foods products through e-commerce in an online store, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.

CEO	Ms. Janet Hall
WEBSITE	guardionhealth.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	12

Guardion Health Sciences Inc Frequently Asked Questions

What is the ticker symbol for Guardion Health Sciences Inc? What does GHSI stand for in stocks?

GHSI is the stock ticker symbol of Guardion Health Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Guardion Health Sciences Inc (GHSI)?

As of Fri May 17 2024, market cap of Guardion Health Sciences Inc is 10.93 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GHSI stock?

You can check GHSI's fair value in chart for subscribers.

What is the fair value of GHSI stock?

You can check GHSI's fair value in chart for subscribers. The fair value of Guardion Health Sciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Guardion Health Sciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GHSI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Guardion Health Sciences Inc a good stock to buy?

The fair value guage provides a quick view whether GHSI is over valued or under valued. Whether Guardion Health Sciences Inc is cheap or expensive depends on the assumptions which impact Guardion Health Sciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GHSI.

What is Guardion Health Sciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, GHSI's PE ratio (Price to Earnings) is -2.13 and Price to Sales (PS) ratio is 0.91. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GHSI PE ratio will change depending on the future growth rate expectations of investors.